MADRID, Spain and CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Manuel López-Figueroa of Bay City Capital as an independent director. Dr. López-Figueroa will be Lead Director and member of the Remuneration and Nomination Committee.
Manuel López-Figueroa, PhD, is a Managing Director at Bay City Capital and has been with the firm since 2001. Bay City Capital is one of the world’s premier life science investment firms investing in over 100 companies and with more than $1.6 billion under management. In addition, Dr López-Figueroa is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, which is comprised of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, the University of California at Irvine, and the HudsonAlpha Institute for Biotechnology. Dr López-Figueroa has over 25 years of experience in the field of neuroscience, has won numerous awards during his academic career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López-Figueroa has a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology. Dr. López-Figueroa serves on the boards of Orfan Biotech (BridgeBio’s Pharma subsidiary), IMIDomics and Zulia Biotech. He is an investment Advisor to Nina Capital and Global Neurohealth Ventures.
Dr. López-Figueroa said: “I’m very pleased to become part of the Board of Directors of Oryzon. I look forward to working with the Board and management to advance novel epigenetic therapeutics and realize Oryzon’s great potential to make an impact on patient treatments and generate significant value for shareholders.”
Dr. López-Figueroa replaces Dr. Vanessa Almendro who stepped down the Board due to sudden arisen incompatibility issues with her Firm. Dr. Carlos Buesa, CEO of Oryzon, wished on behalf of the Board the best professional success in her new responsibilities to Dr. Almendro.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com.
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.
|IR & Media, US & Europe:||Spain:||Oryzon:|
|LifeSci Advisors LLC||ATREVIA||Emili Torrell|
|Hans Herklots||Patricia Cobo/Carlos C. Ungría||BD Director|
|+41 79 598 7149||+34 91 564 07 25||+34 93 515 13 13|